Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation

  • ACS Med Chem Lett. 2026 Feb 23;17(3):621-624. doi: 10.1021/acsmedchemlett.6c00081.
Anna C Renner  1 ,  Robert B Kargbo  2
Affiliations
  • 1. North Dakota State University, Fargo, North Dakota 58108-6050, United States.
  • 2. Independent Research Consultant, Middleton, Wisconsin 53562, United States.
PMID: 41847641 DOI: 10.1021/acsmedchemlett.6c00081
Abstract

Recent patent disclosures from Gilead Sciences reveal a coordinated, multimodal strategy to control STAT6 signaling therapeutically. Small-molecule modulators provide tunable, tissue-focused pathway attenuation, while heterobifunctional degraders enable more profound and potentially more durable suppression. Together, these inventions define STAT6 as a context-sensitive target whose optimal intervention depends on disease biology, exposure, and required depth of pathway control.

Products